USP14 and endometrial cancer: As shown in Figure 4B, pharmacological inhibition of USP14 caused dose-dependent inhibition of cell viability in endometrial cancer cell lines with an IC50 of 181.3 and 117.5 nM for HEC155 (left panel) and ECC1 (right panel), respectively.